kynurenine has been researched along with Chronic Hepatitis C in 12 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined serum kynurenine levels in patients with chronic hepatitis C virus infection, and the relationship between serum kynurenine and prognosis in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C." | 7.96 | Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma. ( Abiru, S; Bekki, S; Beppu, A; Hashimoto, S; Ito, M; Komori, A; Kugiyama, Y; Kuroki, T; Nagaoka, S; Nakamura, M; Saeki, A; Suehiro, T; Yamasaki, K; Yatsuhashi, H, 2020) |
| "We evaluated 101 patients with chronic hepatitis C treated with PEG-IFN-α2a, and 40 controls, so as to determine the activation of indolamine 2,3-dioxygenase (IDO) and tryptophan (TRP) and their metabolites' concentrations/levels: kynurenine (KYN), kynurenic acid (KYNA) and anthranilic acid (AA)." | 7.88 | Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment. ( Inglot, M; Laskus, T; Malyszczak, K; Pawlak, D; Pawlowski, T; Radkowski, M; Zalewska, M, 2018) |
| "The currently recommended therapy for chronic hepatitis C (HCV) is a combination of pegylated interferon-alpha (PEG-IFN alpha) and ribavirin." | 7.77 | Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. ( Bernardinello, E; Bertazzo, A; Cavalletto, L; Chemello, L; Comai, S; Costa, CV; Ragazzi, E, 2011) |
| "During IFN-α treatment Hamilton Depression Rating Scale scores rise significantly." | 5.42 | Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis. ( Amouzadeh-Ghadikolai, O; Baranyi, A; Breitenecker, RJ; Meinitzer, A; Rothenhäusler, HB; Stauber, R, 2015) |
| " We evaluated the relationships between total score on the Montgomery-Åsberg Depression Rating Scale and kynurenine, tryptophan, anthranilic acid and kynurenic acid concentrations, IDO activity and tryptophan availability to the brain." | 4.02 | The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin. ( Bugajska, J; Inglot, M; Janocha-Litwin, J; Malyszczak, K; Marciniak, D; Pawlak, D; Pawlowski, T; Zalewska, M, 2021) |
| "We examined serum kynurenine levels in patients with chronic hepatitis C virus infection, and the relationship between serum kynurenine and prognosis in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C." | 3.96 | Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma. ( Abiru, S; Bekki, S; Beppu, A; Hashimoto, S; Ito, M; Komori, A; Kugiyama, Y; Kuroki, T; Nagaoka, S; Nakamura, M; Saeki, A; Suehiro, T; Yamasaki, K; Yatsuhashi, H, 2020) |
| "We evaluated 101 patients with chronic hepatitis C treated with PEG-IFN-α2a, and 40 controls, so as to determine the activation of indolamine 2,3-dioxygenase (IDO) and tryptophan (TRP) and their metabolites' concentrations/levels: kynurenine (KYN), kynurenic acid (KYNA) and anthranilic acid (AA)." | 3.88 | Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment. ( Inglot, M; Laskus, T; Malyszczak, K; Pawlak, D; Pawlowski, T; Radkowski, M; Zalewska, M, 2018) |
| "The currently recommended therapy for chronic hepatitis C (HCV) is a combination of pegylated interferon-alpha (PEG-IFN alpha) and ribavirin." | 3.77 | Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. ( Bernardinello, E; Bertazzo, A; Cavalletto, L; Chemello, L; Comai, S; Costa, CV; Ragazzi, E, 2011) |
| " In this study, we investigated whether indoleamine 2,3-dioxygenase1 (IDO1)-mediated tryptophan (TRP) metabolism plays a critical role in depression occurring as a side effect of IFN-α therapy." | 1.43 | Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1. ( Fujigaki, H; Imamura, Y; Ishibashi, T; Kim, HC; Kubo, H; Mamiya, T; Mitani, S; Murakami, Y; Nabeshima, T; Nishikawa, M; Ohta, Y; Saito, K; Takahashi, Y; Takakura, Y; Tashiro, T; Tomita, E; Watcharanurak, K; Yamamoto, Y, 2016) |
| "During IFN-α treatment Hamilton Depression Rating Scale scores rise significantly." | 1.42 | Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis. ( Amouzadeh-Ghadikolai, O; Baranyi, A; Breitenecker, RJ; Meinitzer, A; Rothenhäusler, HB; Stauber, R, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bekki, S | 1 |
| Hashimoto, S | 1 |
| Yamasaki, K | 1 |
| Komori, A | 1 |
| Abiru, S | 1 |
| Nagaoka, S | 1 |
| Saeki, A | 1 |
| Suehiro, T | 1 |
| Kugiyama, Y | 1 |
| Beppu, A | 1 |
| Kuroki, T | 1 |
| Nakamura, M | 1 |
| Ito, M | 1 |
| Yatsuhashi, H | 1 |
| Pawlowski, T | 2 |
| Pawlak, D | 2 |
| Inglot, M | 2 |
| Zalewska, M | 2 |
| Marciniak, D | 1 |
| Bugajska, J | 1 |
| Janocha-Litwin, J | 1 |
| Malyszczak, K | 2 |
| Radkowski, M | 1 |
| Laskus, T | 1 |
| Baranyi, A | 2 |
| Meinitzer, A | 2 |
| Stepan, A | 1 |
| Putz-Bankuti, C | 1 |
| Breitenecker, RJ | 2 |
| Stauber, R | 2 |
| Kapfhammer, HP | 1 |
| Rothenhäusler, HB | 2 |
| Amouzadeh-Ghadikolai, O | 1 |
| Murakami, Y | 1 |
| Ishibashi, T | 1 |
| Tomita, E | 1 |
| Imamura, Y | 1 |
| Tashiro, T | 1 |
| Watcharanurak, K | 1 |
| Nishikawa, M | 1 |
| Takahashi, Y | 1 |
| Takakura, Y | 1 |
| Mitani, S | 1 |
| Fujigaki, H | 1 |
| Ohta, Y | 1 |
| Kubo, H | 1 |
| Mamiya, T | 1 |
| Nabeshima, T | 1 |
| Kim, HC | 1 |
| Yamamoto, Y | 1 |
| Saito, K | 1 |
| Vignau, J | 1 |
| Costisella, O | 1 |
| Canva, V | 1 |
| Imbenotte, M | 1 |
| Duhamel, A | 1 |
| Lhermitte, M | 1 |
| Comai, S | 1 |
| Cavalletto, L | 1 |
| Chemello, L | 1 |
| Bernardinello, E | 1 |
| Ragazzi, E | 1 |
| Costa, CV | 1 |
| Bertazzo, A | 1 |
| Wichers, MC | 1 |
| Koek, GH | 1 |
| Robaeys, G | 1 |
| Verkerk, R | 2 |
| Scharpé, S | 1 |
| Maes, M | 2 |
| Cozzi, A | 2 |
| Zignego, AL | 2 |
| Carpendo, R | 1 |
| Biagiotti, T | 1 |
| Aldinucci, A | 2 |
| Monti, M | 1 |
| Giannini, C | 2 |
| Rosselli, M | 2 |
| Laffi, G | 2 |
| Moroni, F | 2 |
| Carpenedo, R | 1 |
| Biagioli, T | 1 |
| Bonaccorso, S | 1 |
| Marino, V | 1 |
| Puzella, A | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Artini, M | 1 |
| Almerighi, C | 1 |
| Meltzer, H | 1 |
2 trials available for kynurenine and Chronic Hepatitis C
| Article | Year |
|---|---|
IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Topics: Adult; Depression; Dioxygenases; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunother | 2005 |
Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2002 |
10 other studies available for kynurenine and Chronic Hepatitis C
| Article | Year |
|---|---|
Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis C, C | 2020 |
The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Major; Female; He | 2021 |
Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment.
Topics: Adult; Antiviral Agents; Depression; Depressive Disorder; Female; Hepatitis C; Hepatitis C, Chronic; | 2018 |
A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection.
Topics: Adult; Analysis of Variance; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Indoleamine- | 2013 |
Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis.
Topics: Adult; Antiviral Agents; Depression; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Kynuren | 2015 |
Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1.
Topics: Animals; Behavior, Animal; Depression; Enzyme Induction; Female; Frontal Lobe; Hepatitis C, Chronic; | 2016 |
[Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
Topics: Adult; Antiviral Agents; Anxiety Disorders; Blood Platelets; Depressive Disorder; Female; Hepatitis | 2009 |
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Case-Control Studies; Depression; Drug Therapy, Combination; Female; Hepati | 2011 |
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients.
Topics: Adult; Anxiety; Depression; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoleamine-Pyrrole 2 | 2006 |
HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Indoleamine-Pyrro | 2007 |